Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
41.82
-0.87 (-2.04%)
At close: Aug 25, 2025, 4:00 PM
41.82
0.00 (0.00%)
After-hours: Aug 25, 2025, 4:00 PM EDT
Ionis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 15 analysts that cover Ionis Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $60.2, which forecasts a 43.95% increase in the stock price over the next year. The lowest target is $39 and the highest is $82.
Price Target: $60.2 (+43.95%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ionis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 5 | 6 |
| Buy | 6 | 4 | 4 | 4 | 5 | 5 |
| Hold | 6 | 6 | 6 | 5 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Total | 19 | 18 | 18 | 17 | 14 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Hold Maintains $48 → $49 | Hold | Maintains | $48 → $49 | +17.17% | Aug 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +31.52% | Aug 25, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $65 → $69 | Strong Buy | Maintains | $65 → $69 | +64.99% | Aug 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $62 → $65 | Buy | Maintains | $62 → $65 | +55.43% | Aug 22, 2025 |
| Barclays | Barclays | Buy Maintains $57 → $58 | Buy | Maintains | $57 → $58 | +38.69% | Aug 22, 2025 |
Financial Forecast
Revenue This Year
876.52M
from 705.14M
Increased by 24.30%
Revenue Next Year
941.31M
from 876.52M
Increased by 7.39%
EPS This Year
-2.57
from -3.04
EPS Next Year
-2.94
from -2.57
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 999.8M | 1.4B | 1.7B | ||
| Avg | 876.5M | 941.3M | 1.3B | ||
| Low | 821.1M | 722.8M | 864.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 41.8% | 62.1% | 82.7% | ||
| Avg | 24.3% | 7.4% | 33.7% | ||
| Low | 16.4% | -17.5% | -8.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.50 | -1.60 | -0.65 | ||
| Avg | -2.57 | -2.94 | -1.80 | ||
| Low | -2.86 | -4.38 | -3.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.